

**Date:** 25 April 2019

## Approval and ethical review of Gubra studies including the diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH)

---

Studies at Gubra including the diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH) are carried out under the Danish Animal Experimentation Act (BEK nr 88 of 30/01/2013) which is stricter and therefore fully compliant with the European directive (2010/63/EU). The specific study designs and models used at Gubra are approved and licensed by the Animal Experiments Inspectorate. For studies including the diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH) licence no. 2013-15-2934-00784 applies.

Furthermore, these animal experiments are conducted in accordance with Gubra's own bioethical guidelines, which are fully compliant to the internationally accepted principles for the care and use of laboratory animals. That these studies fulfil these ethical standards is reviewed by Gubra's Animal Welfare and Ethical Review Body.



Philip G. J. Pedersen, DVM, PhD  
Animal Welfare Officer, Gubra

June 18, 2019

## IACUC Approval

All animal experiments were conducted in accordance with policies of the NIH Guide for the Care and Use of Laboratory Animals and the Institutional Animal Care and Use Committee (IACUC) of AstraZeneca. Specific protocols used in this study were approved under protocol number MI-17-0005.

1.	General Information:	
	Protocol Number:	MI-17-0005.A9
	Protocol Title:	Pharmacological interventions for the treatment of non-alcoholic steatohepatitis (NASH) in mice.
	Principal Investigator:	Victor Howard
	Date Submitted:	23 May 2019
	Length of Protocol:	3 years
	Protocol Status:	Approved
	Date Approved:	29-May-2019